RU2018122012A - БИС-пиридазиновые соединения и их применение в лечении рака - Google Patents
БИС-пиридазиновые соединения и их применение в лечении рака Download PDFInfo
- Publication number
- RU2018122012A RU2018122012A RU2018122012A RU2018122012A RU2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A RU 2018122012 A RU2018122012 A RU 2018122012A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- methoxy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 4
- UXMWOEBIPQMAQT-UHFFFAOYSA-N 3-pyridazin-3-ylpyridazine Chemical class C1=CN=NC(C=2N=NC=CC=2)=C1 UXMWOEBIPQMAQT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 17
- 150000003839 salts Chemical class 0.000 claims 15
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 5
- -1 methoxy, difluoromethoxy Chemical group 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- XDPRJLVJLXPHBD-QRWLVFNGSA-N (2S)-2-[3-(difluoromethoxy)phenyl]-2-methoxy-N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]acetamide Chemical compound FC(OC=1C=C(C=CC=1)[C@@H](C(=O)NC=1N=NC(=CC=1)N1C[C@@H](CC1)NC=1N=NC=CC=1)OC)F XDPRJLVJLXPHBD-QRWLVFNGSA-N 0.000 claims 1
- RJOPJBXFAUPDHA-IERDGZPVSA-N (2S)-2-methoxy-2-(3-methoxyphenyl)-N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]acetamide Chemical compound CO[C@H](C(=O)NC=1N=NC(=CC=1)N1C[C@@H](CC1)NC=1N=NC=CC=1)C1=CC(=CC=C1)OC RJOPJBXFAUPDHA-IERDGZPVSA-N 0.000 claims 1
- BGNWFGWBILIFNL-QRWLVFNGSA-N (2S)-2-methoxy-N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]-2-[3-(trifluoromethoxy)phenyl]acetamide Chemical compound FC(OC=1C=C(C=CC=1)[C@@H](C(=O)NC=1N=NC(=CC=1)N1C[C@@H](CC1)NC=1N=NC=CC=1)OC)(F)F BGNWFGWBILIFNL-QRWLVFNGSA-N 0.000 claims 1
- JODBTGRGROIVCK-MRXNPFEDSA-N 2-(2-methoxyphenyl)-N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]acetamide Chemical compound COC1=C(C=CC=C1)CC(=O)NC=1N=NC(=CC=1)N1C[C@@H](CC1)NC=1N=NC=CC=1 JODBTGRGROIVCK-MRXNPFEDSA-N 0.000 claims 1
- OHDLMZVJIGLCAX-OAHLLOKOSA-N N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]-2-[2-(trifluoromethoxy)phenyl]acetamide Chemical compound N1=NC(=CC=C1)N[C@H]1CN(CC1)C1=CC=C(N=N1)NC(CC1=C(C=CC=C1)OC(F)(F)F)=O OHDLMZVJIGLCAX-OAHLLOKOSA-N 0.000 claims 1
- OTCWMVAEXPSBAB-OAHLLOKOSA-N N-[6-[(3R)-3-(pyridazin-3-ylamino)pyrrolidin-1-yl]pyridazin-3-yl]-2-[2-(trifluoromethyl)phenyl]acetamide Chemical compound N1=NC(=CC=C1)N[C@H]1CN(CC1)C1=CC=C(N=N1)NC(CC1=C(C=CC=C1)C(F)(F)F)=O OTCWMVAEXPSBAB-OAHLLOKOSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1520959.6 | 2015-11-27 | ||
| GBGB1520959.6A GB201520959D0 (en) | 2015-11-27 | 2015-11-27 | Bis-pyridazine compounds and their use in treating cancer |
| PCT/EP2016/078899 WO2017089587A1 (en) | 2015-11-27 | 2016-11-25 | Bis-pyridazine compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018122012A true RU2018122012A (ru) | 2019-12-30 |
Family
ID=55177338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018122012A RU2018122012A (ru) | 2015-11-27 | 2016-11-25 | БИС-пиридазиновые соединения и их применение в лечении рака |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106552296B (zh) | 2015-09-29 | 2020-08-14 | 上海氪励铵勤科技发展有限公司 | 纳米粒子、其制备方法与结石取出装置及应用 |
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| KR20250137464A (ko) | 2024-03-11 | 2025-09-18 | 이석재 | 숏블라스트머신의 연마재탱크 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402305WA (en) | 2011-11-21 | 2014-06-27 | Calithera Biosciences Inc | Heterocyclic inhibitors of glutaminase |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| CN105960405B (zh) | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201730188A (zh) | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201731511A (zh) | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
| TW201733587A (zh) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
-
2015
- 2015-11-27 GB GBGB1520959.6A patent/GB201520959D0/en not_active Ceased
-
2016
- 2016-11-23 US US15/360,332 patent/US10196382B2/en not_active Expired - Fee Related
- 2016-11-25 EP EP16801774.7A patent/EP3380468B8/en active Active
- 2016-11-25 DK DK16801774.7T patent/DK3380468T3/da active
- 2016-11-25 AU AU2016360970A patent/AU2016360970B2/en not_active Ceased
- 2016-11-25 SG SG11201803814SA patent/SG11201803814SA/en unknown
- 2016-11-25 ES ES16801774T patent/ES2806723T3/es active Active
- 2016-11-25 RU RU2018122012A patent/RU2018122012A/ru not_active Application Discontinuation
- 2016-11-25 TW TW105138848A patent/TW201731837A/zh unknown
- 2016-11-25 WO PCT/EP2016/078899 patent/WO2017089587A1/en not_active Ceased
- 2016-11-25 KR KR1020187017944A patent/KR20180083426A/ko not_active Withdrawn
- 2016-11-25 CN CN201680064313.0A patent/CN108349951B/zh not_active Expired - Fee Related
- 2016-11-25 JP JP2018526706A patent/JP2018535226A/ja not_active Withdrawn
- 2016-11-25 CA CA3005102A patent/CA3005102A1/en not_active Abandoned
- 2016-11-25 MX MX2018006374A patent/MX2018006374A/es unknown
- 2016-11-29 AR ARP160103650A patent/AR106849A1/es unknown
-
2018
- 2018-05-14 IL IL259358A patent/IL259358A/en unknown
-
2019
- 2019-02-04 US US16/266,361 patent/US10577354B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3380468A1 (en) | 2018-10-03 |
| SG11201803814SA (en) | 2018-06-28 |
| IL259358A (en) | 2018-07-31 |
| GB201520959D0 (en) | 2016-01-13 |
| AR106849A1 (es) | 2018-02-21 |
| US20190169172A1 (en) | 2019-06-06 |
| CA3005102A1 (en) | 2017-06-01 |
| US10577354B2 (en) | 2020-03-03 |
| EP3380468B8 (en) | 2020-11-04 |
| EP3380468B1 (en) | 2020-05-20 |
| CN108349951B (zh) | 2020-11-13 |
| US20170152244A1 (en) | 2017-06-01 |
| MX2018006374A (es) | 2019-07-08 |
| ES2806723T3 (es) | 2021-02-18 |
| JP2018535226A (ja) | 2018-11-29 |
| CN108349951A (zh) | 2018-07-31 |
| TW201731837A (zh) | 2017-09-16 |
| AU2016360970B2 (en) | 2019-11-07 |
| US10196382B2 (en) | 2019-02-05 |
| AU2016360970A1 (en) | 2018-07-05 |
| WO2017089587A1 (en) | 2017-06-01 |
| DK3380468T3 (da) | 2020-07-27 |
| KR20180083426A (ko) | 2018-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2460730C2 (ru) | Новые производные n-(8-гетероарилтетрагидронафталин-2-ил)-или n-(5-гетероарилхроман-3-ил)-карбоксамида для лечения боли | |
| PH12019501707A1 (en) | N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor | |
| RU2018123714A (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2019517487A5 (cg-RX-API-DMAC7.html) | ||
| RU2017105353A (ru) | Соединения | |
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| IL264982B (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2016515561A5 (cg-RX-API-DMAC7.html) | ||
| EA201690959A1 (ru) | Способ синтеза ингибитора индоламин-2,3-диоксигеназы | |
| EA201892746A1 (ru) | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида | |
| RU2018122012A (ru) | БИС-пиридазиновые соединения и их применение в лечении рака | |
| JP2017505293A5 (cg-RX-API-DMAC7.html) | ||
| JP2016522254A5 (cg-RX-API-DMAC7.html) | ||
| JP2017517512A5 (cg-RX-API-DMAC7.html) | ||
| RU2017145649A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АНТИТЕЛА К CD20 В СОЧЕТАНИИ С ИНГИБИТОРОМ BeI-2 И ИНГИБИТОРОМ MDM2 | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2018535986A5 (cg-RX-API-DMAC7.html) | ||
| RU2017117566A (ru) | Активатор kcnq2-5 каналов | |
| JP2015521195A5 (cg-RX-API-DMAC7.html) | ||
| JP2018535235A5 (cg-RX-API-DMAC7.html) | ||
| RU2016132858A (ru) | Производные фторнафтила | |
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191126 |